Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson
October 01, 2020 08:44 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel...
Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson
September 15, 2020 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel...
Momenta Enters Definitive Agreement with Johnson & Johnson
August 19, 2020 06:34 ET
|
Momenta Pharmaceuticals, Inc.
Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020 ...
Momenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results
August 10, 2020 07:00 ET
|
Momenta Pharmaceuticals, Inc.
-- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p<0.0001) between...
Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast
August 03, 2020 07:30 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
July 28, 2020 07:15 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease...
Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)
June 15, 2020 07:05 ET
|
Momenta Pharmaceuticals, Inc.
- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001) - - Nipocalimab induced a rapid and durable response...
Momenta Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results
May 07, 2020 07:00 ET
|
Momenta Pharmaceuticals, Inc.
-- Top-line interim data from nipocalimab Vivacity-MG study expected by Q3 2020 -- -- Full data from Part B of Phase 1/2 study of M254 in ITP expected in Q3 2020 -- -- Initiated IND-enabling studies...
Momenta Pharmaceuticals Announces Date of First Quarter 2020 Financial Results Conference Call and Webcast
April 23, 2020 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Provides Corporate Update Amid COVID-19 Pandemic
April 02, 2020 07:30 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...